Newsroom
All news stories
Latest news

Featured
Hikma launches Triamcinolone Acetonide Injectable Suspension, USP, in the US
Press Release, Product
05 June 2025
- Hikma launches Triamcinolone Acetonide Injectable Suspension, USP, in the US Press Release, Product 05 June 2025 Hikma launches Triamcinolone Acetonide Injectable Suspension, USP, in the US
- Fitch upgrades Hikma Pharmaceuticals PLC’s long-term issuer default rating to ‘BBB’, outlook stable Press Release, Corporate 29 May 2025 Fitch upgrades Hikma Pharmaceuticals PLC’s long-term issuer default rating to ‘BBB’, outlook stable
- Bio-Thera Solutions and Hikma Pharmaceuticals announce FDA approval of STARJEMZA® (ustekinumab-hmny) Injection, a biosimilar referencing STELARA® (ustekinumab) Injection Press Release, Product 27 May 2025 Bio-Thera Solutions and Hikma Pharmaceuticals announce FDA approval of STARJEMZA® (ustekinumab-hmny) Injection, a biosimilar referencing STELARA® (ustekinumab) Injection
- Hikma announces strong medium-term Group guidance ahead of its US site visit Press Release, Corporate 15 May 2025 Hikma announces strong medium-term Group guidance ahead of its US site visit